The study, at two academic departments of ophthalmology, is designed to assess the safety and efficacy of the Aquashunt and will enroll up to 20 patients with significantly impaired visual acuity.
The Aquashunt is a novel device designed to lower intraocular pressure by allowing excess fluid in the eye to exit more naturally than occurs with presently available devices.
Bruce Shields, professor of ophthalmology at Yale University and designer of the Aquashunt, said: “We are pleased by the simplicity of the surgical procedure for the device and by the early results in the first human trials. These early results provide further validation of our optimism for the future of the Aquashunt, and we look forward to completing our clinical trials and bringing this product to market.”